Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Anthony Elias et al.|JAMA Oncology|2020Cited by 707
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29